AKT1 and B-cell chronic lymphocytic leukemia: Notably, ILK inhibition has been demonstrated to suppress both PI3K/AKT signalling and MAPK/ERK activation in prostate cancer and chronic lymphocytic leukaemia (CLL) cell lines [74–76].